<DOC>
	<DOCNO>NCT02628704</DOCNO>
	<brief_summary>Double-blind study compare efficacy assess safety selinexor plus carfilzomib ( Kyprolis® ) plus low-dose dexamethasone versus placebo plus carfilzomib plus low-dose dexamethasone patient relapsed/refractory multiple myeloma .</brief_summary>
	<brief_title>Selinexor , Carfilzomib , Dexamethasone Versus Placebo , Carfilzomib , Dexamethasone Multiple Myeloma</brief_title>
	<detailed_description>This Phase 2 , two-arm , randomize , placebo-controlled , double-blind , multicenter study relapsed/refractory multiple myeloma patient receive least two prior therapy , include proteasome inhibitor IMiD . Patients meet eligibility criterion randomize one two blind treatment arm : - selinexor + carfilzomib + dexamethasone - placebo + carfilzomib + dexamethasone</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Symptomatic , histologically confirm MM , base IMWG guideline . Patients must measurable disease define least one following : Serum Mprotein ≥ 1.0 g/dL serum protein electrophoresis ( SPEP ) immunoglobulin ( Ig ) A myeloma , quantitative IgA ; Urinary Mprotein excretion least 200 mg/24 hour ; Serum FLC ≥ 100 mg/L , provide serum FLC ratio abnormal . If serum protein electrophoresis felt unreliable routine M protein measurement , quantitative Ig level nephelometry turbidometry acceptable . Must receive ≥ 2 prior antiMM therapy include proteasome inhibitor IMiD . The recent proteasome inhibitor must carfilzomib . Patients previously treat carfilzomib eligible long meet follow criterion : Not receive carfilzomib within 6 month ( 183 day ) Cycle 1 Day 1 ( C1D1 ) , Carfilzomib part recent therapy treatment MM , Did discontinue carfilzomib treatment adverse effect . MM refractory recent treatment regimen . Refractory define ≤ 25 % response therapy , progression therapy , progression within 60 day completion therapy . Smoldering MM . Active plasma cell leukemia . MM express Mprotein serum FLC ( i.e. , nonsecretory MM exclude ; plasmacytomas without Mprotein serum FLC exclude ) . Documented active systemic amyloid light chain amyloidosis . Active MM involve central nervous system . Active polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy , skin change ( POEMS ) syndrome . Prior autologous stem cell transplantation &lt; 1 month allogenic stem cell transplantation &lt; 3 month prior C1D1 . Active graft versus host disease ( allogeneic stem cell transplantation ) C1D1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Karyopharm</keyword>
	<keyword>selinexor</keyword>
	<keyword>KPT-330</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>SCORE</keyword>
</DOC>